我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

黄嘌呤氧化酶在HFrEF患者血清中的水平及相关因素

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2016年第6期
页码:
697-700
栏目:
临床研究
出版日期:
2016-07-05

文章信息/Info

Title:
Relevant factors and levels of serum XO in heart failure patients with reduced ejection fraction
作者:
张子龙1; 高方明2; 张晓云2
（1.石河子大学医学院心内科,新疆 石河子 832002；2.新疆自治区人民医院心内科,新疆 乌鲁木齐 830000）
Author(s):
ZHANG Zi-long1;  GAO Fang-ming2;  ZHANG Xiao-yun2
(1.Department of Cardiology, MedicalCollege, Shihezi University, Shihezi 832002, Xinjiang, China；
2.Department of Cardiology, Xinjiang Autonomous Region People’s Hospital, Urumqi 830000, Xinjiang, China)
关键词:
心力衰竭; 慢性; 黄嘌呤氧化酶; 心脏脂肪酸结合蛋白; 金属蛋白酶-2; 金属蛋白酶-9
Keywords:
heart failure;  xanthine oxidase;  heart fatty acid binding protein;  metalloproteinase-2;  -9
分类号:
R541.6
DOI:
-
文献标识码:
A
摘要:
目的 探讨射血分数减低的心力衰竭（HFrEF）患者血清中黄嘌呤氧化酶（XO）水平及其与心脏脂肪酸结合蛋白（H-FABP）,金属蛋白酶（MMP）-2，MMP-9的相关性。方法 选取新疆维吾尔自治区人民医院心内科住院确诊为HFrEF患者40例（HFrEF组），健康体检正常者40例（对照组），分别测量两组患者的身高 、体质量、血压 ，留取空腹静脉血，采用酶联免疫吸附实验分别检测两组血清中XO、H-FABP、MMP-2、MMP-9水平。结果 与对照组比较，HFrEF组患者血清中XO水平显著高于对照组（P<0.05）。多元线性逐步回归分析显示，H-FABP,MMP-2和MMP-9是影响血清XO水平的独立相关因素。 HFrEF组患者血清XO水平与H-FABP,MMP-2和MMP-9呈正相关（分别r=0.787,r=0.838和r=0.864，均P<0.01）。结论 HFrEF患者血清中XO水平均显著增高， 且血浆XO水平与H-FABP,MMP-2和MMP-9相关。
Abstract:
AIM To investigate the levels of serum xanthine oxidase (XO) in heart failure patients with reduced ejection fraction (EF) and to study the possible correlations of serum XO levels with heart fatty acid binding protein (H-FABP) and matrix metalloproteinases-2, -9 (MMP-2, MMP-9). METHODSA total of 80 patients who were hospitalized or undergoing physical examination at the People’s Hospital of Xinjiang Uygur Autonomous Region were divided into heart failure with decreased EF group (n=40) and control group (n=40). Height, weight and blood pressure were measured in all patients. Fasting venous blood samples were collected and the levels of serum XO, H-FABP, MMP-2 and MMP-9 were tested by enzyme-linked immunosorbent assay (ELISA). RESULTSCompared with control group, serum XO levels in heart failure group significantly increased (P<0.05). In heart failure group, serum XO levels were positively correlated with H-FABP, MMP-2 and MMP-9 (r=0.787, 0.838 and 0.864, respectively; P<0.01). Multiple linear stepwise regression analysis showed that H-FABP and MMP-2 and MMP-9 were independent factors affecting serum XO levels (P<0.01). CONCLUSIONSerum XO levels in heart failure patients with reduced ejection fraction decrease significantly and serum XO levels are associated with heart fatty acid binding protein and matrix metalloproteinases-2, -9.

参考文献/References

[1]Ellidag HY,Eren E,Yilmaz N,et al.Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure[J].Redox Rep,2014,19(3):118-123.
[2]Okonko DO,Shah AM.Heart failure: mitochondrial dysfunction and oxidative stress in CHF[J].Nat Rev Cardiol,2015,12(1):6-8.
[3]Bhimaraj A,Tang WH.Role of oxidative stress in disease progression in Stage B,a pre-cursor of heart failure[J].Heart Fail Clin,2012,8(1):101-111.
[4]Gotsman I,Keren A,Lotan C,et al.Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival[J].J Card Fail,2012,18(9):694-701.
[5]Kaufman M,Guglin M.Uric acid in heart failure:a biomarker or therapeutic target[J].Heart Fail Rev,2013,18(2):177-186.
[6]Isik T,Ayhan E,Ergelen M,et al.Uric acid:a novel prognostic marker for cardiovascular disease[J].Int J Cardiol,2012,156(3):328-329.
[7]Baldasseroni S,Urso R,Maggioni AP,et al.Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index:data from the IN-CHF Registry[J].Nutr Metab Cardiovasc Dis,2012,22(5):442-448.
[8]Zhang Y,Tocchetti CG,Krieg T,et al.Oxidative and nitrosative stress in the maintenance of myocardial function[J].Free Radic Biol Med,2012,53(8):1531-1540.
[9]Groote PD,Mouquet F,Lamblin N,et al.Serum Uric Acid is a Powerful Predictor of Survival in Patients With Stable Chronic Heart Failure Receiving Beta-Blocker Therapy[J].Circulation,2007,116:II 650.
[10]Duan X,Ling F.Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure?[J].Med Hypotheses,2008,70(3):578-581.
[11]Bergamini C,Cicoira M,Rossi A,et al.Oxidative stress and hyperuricaemia:pathophysiology, clinical relevance,and therapeutic implications in chronic heart failure[J].Eur J Heart Fail,2009,11(5):444-452.
[12]Strazzullo P,Puig JG.Uric acid and oxidative stress:relative impact on cardiovascular risk[J].Nutr Metab Cardiovasc Dis,2007,17(6):409-414.
[13]Niizeki T,Takeishi Y,Arimoto T,et al.Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure[J].Circ J,2008,72(1):109-114.
[14]Tsutsui H,Tsuchihashi-Makaya M,Kinugawa S,et al.Characteristics and outcomes of patients with heart failure in general practices and hospitals[J].Circ J,2007,71(4):449-454.
[15]Brouwers FP,van Gilst WH,van Veldhuisen DJ.The changing face of heart failure:are we really making progress[J].Eur J Heart Fail,2013,15(9):960-962.
[16]Cesselli D,Jakoniuk I,Barlucchi L,et al.Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy[J].Circ Res,2001,89(3):279-286.

备注/Memo

备注/Memo:
收稿日期：2015-10-25.
通讯作者：高方明，主任医师,主要从事心血管疾病研究Email:gaofangming@sohu.com
作者简介：张子龙，住院医师，硕士Email：710707787@qq.com
更新日期/Last Update: 2016-07-10